IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Influx Healthtech IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Mumbai and caters to Healthcare sector. Rarever Financial Advisors Private is the merchant banker of Influx Healthtech IPO. It is a SME UPCOMING IPO which filed its Draft Red Herring Prospectus (DRHP) on 4th February 2025.
Influx Healthtech IPO posted revenues of Rs 94.92 crores and PAT of Rs 12.06 crores in FY25 on annualised basis.Financial results of Influx Healthtech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Influx Healthtech IPO PAT Margin is 9.52%, ROCE (Return on Capital Employed) is 10.27% as per latest financial. The below table shows Influx Healthtech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Influx Healthtech IPO is Rs [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Influx Healthtech IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Influx Healthtech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Influx Healthtech IPO is ₹[●] Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Influx Healthtech IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Influx Healthtech IPO reported revenue of ₹94.92 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Influx Healthtech IPO provide insights into sales growth, market demand, and business scalability.
Influx Healthtech recorded an EBITDA of ₹ 4.77 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Influx Healthtech Profit After Tax (PAT) is ₹3.02 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 31.68 Cr.
EBITDA Margin:
15.06
%
Net Worth: ₹ 24.89 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Influx Healthtech operates in Healthcare and . The Issue is listed on NSE EMERGE in Apr, 2025. Influx Healthtech IPO size was with Issue price of .
Merchant Banker(s) of Influx Healthtech IPO: Rarever Financial Advisors Private Limited
Influx Healthtech IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Influx Healthtech IPO listed at a listing price of against the offer price of .
The current market price of Influx Healthtech is .
Why Us?
